The FDA apparently deems an uncontrolled study acceptable – five months after saying no.
ApexOnco Front Page
Recent articles
Could RO7851624, newly into clinical trials, be RG6735?
Emilta-L continues to show worse efficacy than a rival ADC discontinued by Pfizer.
Emrelis becomes the first drug for cMet-positive NSCLC, but only for the highest expressers.
Early data with ELVN-001 hold up well against olverembatinib and TERN-701.
The company deprioritises its lead project, naporafenib, shifting to two Joyo-originated assets.
IBI3020 beats Chengdu Kanghong's KH815 into clinical trials.
GSK and iTeos dump belrestotug, with the latter now looking at “strategic alternatives”.